Press releaseBusiness Wire
Blueprint Medicines
BPMC · NASDAQ
Price unavailable right now.
No price history for this range.
Latest news
- Press releaseBusiness Wire
Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction
- NewsVandana Singh
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
- Press releasePRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: VRNA, BPMC, DALN, and RGLD
- NewsVandana Singh
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SAGE, SOL on Behalf of Shareholders
- Press releaseBusiness Wire
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
- NewsAvi Kapoor
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday
- Press releaseGlobe Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SVT, SSBK on Behalf of Shareholders
- Press releasePRNewswire
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
- NewsAnthony Noto
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
- Press releaseGlobe Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VIGL, STR, BPMC, STRM on Behalf of Shareholders
- Press releaseBusiness Wire
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders
- Press releaseGlobe Newswire
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
- News
Analyst Expectations For Blueprint Medicines's Future
- Press releaseBusiness Wire
Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders
- Press releaseBusiness Wire
BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders
- NewsRishabh Mishra
US Stocks Likely To Open Lower After A Solid May: 'TACO' Trade And 'Run It Hot' Optimism 'Are Consensus At This Point,' Says Expert
- NewsAvi Kapoor
Campbell's, SAIC And 3 Stocks To Watch Heading Into Monday
- Press releasePRNewswire
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
- Press releasePRNewswire
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
- News
Earnings Scheduled For May 1, 2025
- News
Blueprint Medicines Earnings Preview
- News
What Analysts Are Saying About Blueprint Medicines Stock
- Press releasePRNewswire
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
- News
Breaking Down Blueprint Medicines: 14 Analysts Share Their Views
- Press releasePRNewswire
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference
- News
The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Experts
- News
13 Analysts Assess Blueprint Medicines: What You Need To Know
- Press releasePRNewswire
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress
- News
Breaking Down Blueprint Medicines: 10 Analysts Share Their Views
- Press releasePRNewswire
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
- Press releasePRNewswire
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
- NewsLekha Gupta
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
- Press releasePRNewswire
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
- Press releasePRNewswire
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Press releasePRNewswire
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
- Press releasePRNewswire
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
- Press releasePRNewswire
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
- Press releasePRNewswire
Blueprint Medicines to Present at Upcoming Investor Conferences
- Press releasePRNewswire
Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
- News
10 Health Care Stocks Whale Activity In Today's Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.